Table 2 Study outcomes
Outcomes | TXA | Placebo | RD | RR |
|---|---|---|---|---|
(n = 120) | (n = 118) | [95% CI] | [95% CI] | |
Progressive intracranial haemorrhage (PIH) | 21 (18%) | 32 (27%) | −0.10 | 0.65 |
moderate TBI (n = 24) | 7 (6%) | 17 (14%) | [(−0.20)- | [0.40-1.05] |
severe TBI (n = 20) | 9 (8%) | 11 (9%) | (−0.01)] | |
indicated neurosurgery | 6 (5%) | 6 (5%) | ||
Increase in pressure effect* | *11 (10%) | 12 (11%) | −0.01 | 0.91 |
[(−0.09) – 0.07] | [0.42-1.97] | |||
Improved GCS motor score at 24 hours | 37 (31%) | 37 (31%) | −0.01 | 0.98 |
[(−0.12) – 0.11] | [0.67-1.44] | |||
Neurosurgical intervention | 3 (3%) | 0 | 0.03 | --- |
[(−0.00) – 0.05] | --- | |||
Blood products transfusion | 31 (26%) | 33 (28%) | −0.02 | 0.92 |
[(−0.13) – 0.09] | [0.61-1.40] | |||
Death | 12 (10%) | 17 (14%) | −0.04 | 0.69 |
[(−0.13) – 0.04] | [0.35-1.39] | |||
Unfavorable (GOS) outcome | 21 (18%) | 27 (23%) | −0.05 | 0.76 |
[(−0.16) – 0.05] | [0.46-1.27] | |||
Adverse events | ||||
Stroke | 0 | 3 | --- | --- |
Pulmonary embolus | 0 | 0 | --- | --- |
Deep vein thrombosis | 0 | 0 | --- | --- |
Gastrointestinal bleeding | 0 | 1 | --- | --- |